
Chinese subsidiary established on 29 July 2014 in the China (Shanghai) Pilot Free Trade Zone, wholly owned by GRmed Company Limited with fifty million yuan of registered capital, and belonging to Hungary's largest pharmaceutical company. Handles technology development and services in pharmaceutical science and biotechnology together with medical device wholesale, food trading and international trade, and provides promotion, registration, clinical research and patent filing for the group's medical products in the Chinese market. In October 2024 it signed an agreement with Bio-Thera Solutions for exclusive commercialisation rights to the ustekinumab injection BAT2206 in the European Union, the United Kingdom and other territories.
Ver perfil de la empresa
Deja tu valoración